CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

VERONA PHARMA

VRNA
$1.10B
Small Cap
NASDAQPharmaceutical Preparations🇺🇸North AmericaLONDON

Drugs in Pipeline

14

Phase 3 Programs

2

Upcoming Catalysts

3

Next Catalyst

Aug 5, 2026

14w

Market Overview

Stock performance and key metrics

VRNA News
Catalyst Timeline

5 upcoming, 0 past

Phase 2Next

Ensifentrine 3 mg Phase 2 Results Expected

Apr 29, 2026Ensifentrine 3 mg480

Primary completion for Ensifentrine 3 mg trial (NCT07016412) in Chronic Obstructive Pulmonary Disease

Source
Phase 2

Glycopyrrolate 21.25 mcg Phase 2 Results Expected

Apr 29, 2026Glycopyrrolate 21.25 mcg480

Primary completion for Glycopyrrolate 21.25 mcg trial (NCT07016412) in Chronic Obstructive Pulmonary Disease

Source

3 more catalysts beyond 14 days

Start a 48h free trial to see all upcoming catalysts

Pro
Drug Pipeline

Ensifentrine 3 mg twice daily

Phase 3

COPD

Ensifentrine

Phase 3

Chronic Obstructive Pulmonary Disease

Nebulized Ensifentrine Suspension; 3 mg

Phase 2

Non-cystic Fibrosis Bronchiectasis

Part A: RPL554

Phase 2

Pulmonary Disease, Chronic Obstructive

Glycopyrrolate (85 μg)

Phase 2

Chronic Obstructive Pulmonary Disease

Tiotropium/olodaterol (Respimat)

Phase 2

COPD

Ensifentrine 3 mg

Phase 2

Chronic Obstructive Pulmonary Disease

RPL554

Phase 2

Cystic Fibrosis

Salbutamol

Phase 2

Chronic Obstructive Pulmonary Disease

Glycopyrrolate 21.25 mcg

Phase 2

Chronic Obstructive Pulmonary Disease

1.5 mg RPL554 plus tiotropium

Phase 2

Chronic Obstructive Pulmonary Disease Moderate

Ensifentrine Dose 1

Phase 2

Coronavirus Infection

Part B: RPL554

Phase 2

COPD

RPL554 suspension

Phase 2

COPD

Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply